Selank

What Is Selank?

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Institute of Pharmacology.

It is a structural analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg, sequence corresponding to residues 289-292 of the immunoglobulin G heavy chain) released enzymatically from the Fc portion of IgG and originally characterized as an immunomodulatory peptide. Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide, a stabilizing motif also seen in the related research peptide Semax.

In published research literature, Selank is examined for its effects on GABAergic neurotransmission gene expression, monoamine system modulation (serotonin, dopamine, norepinephrine), enkephalin metabolism, BDNF expression, and immunomodulation.

Selank in Plain Language

A non-technical overview of what Selank is, what researchers have studied it for, what early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.

At a glance

Selank is a small lab-made peptide based on a natural protein involved in immune regulation. In research, scientists study it for its effect on anxiety, attention, and the nervous system’s stress response, and notably, without the sedation, dependence, or withdrawal issues linked to traditional anti-anxiety drugs.

Selank is a registered pharmaceutical in Russia, but that registration does not apply in the United States, where it is not FDA-approved for any use. The compound sold here is a research chemical, not a pharmaceutical.

What it is

Selank is a synthetic heptapeptide (seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro). The first four amino acids (Thr-Lys-Pro-Arg) reproduce tuftsin, a naturally occurring four-amino-acid fragment cleaved from immunoglobulin G (IgG) that has been studied since the 1970s for its effects on immune cells.

The C-terminal Pro-Gly-Pro tail is a stabilizing extension, the same kind of stabilizer found in the related research peptide Semax, that researchers describe as helping the molecule resist rapid enzymatic breakdown.

Selank was developed at the M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry / V.V.

Zakusov State Institute of Pharmacology in the Soviet Union and the Russian Federation, and is registered as a prescription medication for anxiety-related indications in Russia. It is not approved for medical use in the United States or in the European Union; outside Russia it is studied in research contexts only.

How Selank is used in Russia (educational context only)

Because Selank has been a registered prescription medicine in the Russian Federation for many years, this is the largest body of real-world clinical experience with the molecule. None of the information below is intended as a medical recommendation, a use instruction, or a claim about BioChain’s research-grade product.

It is included only to help readers understand the international regulatory landscape for this peptide.

• Manufacturer. The branded pharmaceutical product in Russia is sold under the trade name Selank®, manufactured by Peptogen and related Russian pharmaceutical entities, based on intellectual property from the Russian Academy of Sciences.
• Form. The clinical product is distributed primarily as a 0.15 % intranasal solution.
• Approved indications (Russia, summarized). Indications listed in the Russian product registration are anxiety-related and include generalized anxiety disorder, neurasthenic and adjustment disorders, and certain mild-to-moderate anxiety states. Adult prescribing is by a physician under standard pharmaceutical rules.
• Clinical role. In Russian clinical practice, Selank is positioned in the “regulatory peptide / anxiolytic” therapeutic class and is most often prescribed by neurologists or psychiatrists. It is described in Russian clinical literature as a non-benzodiazepine anxiolytic intended for short-to-medium-term courses, and is sometimes discussed as an option for patients in whom benzodiazepine sedation, motor effects, or dependence concerns are a problem. It is also studied in Russian research contexts as an adjunct in mixed anxiety / depressive presentations.
• Safety profile reported in Russian clinical use. Russian product information describes Selank as generally well tolerated, with rare reports of mild nasal irritation. The Russian clinical literature reports no notable sedation or motor impairment, and no reported physical dependence or withdrawal in routine prescribing populations, a profile that is the principal differentiator emphasized in the Russian clinical positioning relative to benzodiazepines. These reports describe the registered pharmaceutical product, administered under medical supervision, in the populations studied; they do not transfer to research-grade material or to other populations.
• Why this is not a U.S. claim. Russian regulatory approval is specific to the registered Russian pharmaceutical product, the populations studied in the Russian dossier, and clinical use under physician supervision. It does not equate to FDA or EMA approval, and it does not mean the molecule is approved or authorized for medical use in the United States. The clinical experience above cannot be translated into therapeutic claims for research-grade material.

Research areas being investigated

• Anxiety / behavioral research: Studied in rodent models for anxiolytic-like behavior without sedation or dependence-like profiles.
• GABA-system gene-expression research: Examined in cell-culture and rodent brain tissue for effects on GABA-A receptor subunit gene expression, without direct binding to the GABA-A receptor.
• BDNF / neuroplasticity research: Investigated for effects on brain-derived neurotrophic factor (BDNF) expression after intranasal administration in rodents.
• Enkephalin / endogenous-opioid research: Studied for effects on the enzymatic breakdown of endogenous opioid peptides (enkephalins).
• Monoamine research: Examined for effects on serotonin, dopamine, and norepinephrine metabolism in rodent brain tissue.
• Tuftsin / immunology research: Used as a stable analog of tuftsin for studying phagocytic activity, IL-6 production, and Th1 / Th2 cytokine balance in immune-cell models.

What the research suggests so far

Animal / preclinical findings. Most published Selank evidence comes from rodent behavioral and neurochemistry models. Researchers have reported anxiolytic-like behavior in elevated plus-maze and similar paradigms without the sedation or motor-impairment effects associated with benzodiazepine compounds.

Intranasal administration in rodents has been associated with BDNF mRNA induction in the hippocampus and region-specific changes in monoamine metabolism. These findings do not, on their own, demonstrate the same effects in humans.

Cell / lab findings. In cell-culture work, Selank has been described as influencing expression of GABA-A receptor subunit genes without binding the receptor directly, and as suppressing enzymatic degradation of leu-enkephalins. Immunology cell-culture work has reported modulation of IL-6 production and phagocytic activity. These mechanistic findings inform hypotheses about how Selank might act in tissue, but they remain preclinical.

Human findings. Most human clinical experience with Selank is concentrated in the Russian Federation, where it has been registered as a prescription medication for anxiety-related indications as described above. Russian-language clinical research has reported reductions in anxiety scale scores in cohorts ranging from small open-label studies to multi-center comparative studies (some with active comparators in the benzodiazepine class). Published clinical experience outside Russia is limited.

There are no large, published Phase III randomized controlled trials in U.S. or European populations. Selank is not approved by the FDA, EMA, or other Western regulators for any use.

Limitations of the evidence. A substantial portion of the Selank literature is published in Russian-language journals or in Russian clinical research, and independent multi-laboratory replication outside Russia is uneven. Long-term safety data and rigorous Western Phase III trials are lacking.

Reviewers in the international peer-reviewed literature have specifically called out the need for additional rigorous human studies before broad therapeutic conclusions can be drawn. Even in jurisdictions where Selank is an approved medicine, those approvals refer to a specific manufactured pharmaceutical product administered under medical supervision, they do not transfer to research-grade chemical material.

Research relevance

Selank is most often discussed in research involving GABA-system gene-expression modulation (without direct receptor binding), BDNF and neuroplasticity, enkephalin metabolism and endogenous opioid signaling, monoamine system modulation, and tuftsin-lineage immunology. Most published findings outside of Russian clinical practice are preclinical, so it should not be presented as a proven treatment for any condition in U.S.

or international markets. Its scientific interest lies in its potential use as a research tool for studying neurochemistry, neuroplasticity, and tuftsin-derived immunology in the laboratory.

What cannot be claimed about Selank

• It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
• It cannot be claimed to treat anxiety, panic disorder, depression, ADHD, PTSD, or any psychiatric condition in humans.
• It cannot be claimed to enhance memory, focus, sleep, or stress resilience.
• It cannot be claimed to be safe or effective for human or veterinary use.
• It cannot be claimed to be approved by the FDA or EMA.
• It cannot be claimed to be equivalent to or a substitute for the Russian pharmaceutical product Selank®.
• It cannot be represented as a dietary supplement.

Summary

Selank is a synthetic heptapeptide based on tuftsin (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro tail. It is studied in laboratory and rodent research related to GABA-system gene expression, BDNF and neuroplasticity, enkephalin metabolism, monoamine modulation, and tuftsin-lineage immunology. It is registered as a prescription medication for anxiety-related indications in Russia, where the registered product Selank® is used under physician supervision. It is not approved by the FDA, EMA, or other Western regulators for any use.

Published evidence outside the Russian clinical literature is dominated by rodent and cell-culture work. BioChain USA’s Selank is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.

Short version

Selank is a synthetic heptapeptide based on the immune-active fragment tuftsin. It is studied in cell and rodent research on the GABA system, BDNF, enkephalin metabolism, and immune signaling. It is a prescription medicine in Russia, but it is not approved by the FDA. Sold for research and laboratory use only.

Source notes

• Volkova A, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol, 2016, cell / molecular study. (PMC4757669.)
• Filatova E, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol, 2017, cell-culture study.
• Inozemtseva LS, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci, 2008, animal study.
• Kost NV, et al. The effect of Selank on the activity of the enkephalin-degrading enzymes in the blood of patients with generalized anxiety disorder. Russian-language clinical neuropharmacology research underpinning the Russian Federation registration of Selank® for anxiety-related indications.
• Russian Federation State Register of Medicines, product registration entry for Selank® intranasal solution, reference to approved anxiety-related indications and dosage form.
• From Tuftsin to Selank, heptapeptide neurochemistry and immunology overview, secondary review article.
• Selank, encyclopedic reference (Wikipedia, secondary source).

Source types: entries 1, 2, 3 are cell / animal studies; entries 4, 5 reference Russian-language clinical pharmacology data and the Russian Federation registry of medicines; entries 6, 7 are secondary review and reference works.

SEO meta description

Selank is a synthetic heptapeptide based on tuftsin, studied in preclinical research on the GABA system, BDNF, enkephalin metabolism, and immune signaling. Research-use only.

Reminder. BioChain USA sells Selank strictly as a research-use-only chemical for qualified laboratory and educational use. It is not approved by the FDA and is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.

Certificate of Analysis (COA)

• COA provided where available for the specific batch shipped.
• The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
• COA information is batch-specific and is not interchangeable between lots.

Frequently Asked Questions